의약품 품질관리 소프트웨어(QMS) 시장 예측(-2030년) : 프로세스별, 용도별, 규모별, 최종사용자별, 지역별

The global pharmaceutical QMS market is projected to reach USD 2.98 billion by 2030 from USD 1.59 billion in 2025, at a CAGR of 13.3% during the forecast period. The pharmaceutical QMS market is experiencing consistent growth, driven by increasing regulatory requirements, the need for streamlined compliance processes, and rising demand for digital transformation in the pharmaceutical industry. Companies are adopting QMS solutions to improve efficiency, minimize errors, and ensure compliance with global standards such as FDA, EMA, and ISO guidelines.

Additionally, the increasing complexity of drug development, clinical trials, and manufacturing operations is further boosting adoption. This trend reflects the industry's move toward integrated, automated, and data-driven quality management systems to enhance overall product quality, patient safety, and accelerate time-to-market efficiency.

"Regulatory compliance under the process segment is expected to register the fastest growth rate during the forecast period."

By process, the regulatory compliance segment is expected to grow the fastest in the pharmaceutical QMS market. This expansion is driven by the growing complexity of global regulatory requirements and the increasing need for pharmaceutical companies to meet stringent quality and safety standards set by agencies such as the FDA, EMA, and WHO. QMS helps organizations efficiently manage audits, documentation, and reporting tasks, thereby reducing the risk of non-compliance and associated penalties. Moreover, the rising demand for automated compliance tracking, real-time data visibility, and centralized document control is boosting the adoption of QMS solutions across the industry.

"CAPA management under the application segment is expected to be the fastest-growing segment during the forecast period."

By application, the CAPA (Corrective and Preventive Action) management segment is expected to be the fastest-growing area in the pharmaceutical QMS market. This growth is fueled by the rising focus on proactively identifying and fixing quality issues to meet regulatory standards. CAPA solutions help pharmaceutical companies systematically investigate root causes, implement corrective actions, and prevent the recurrence of deviations or nonconformities. The increasing integration of automation, data analytics, and real-time monitoring within CAPA processes further boosts efficiency and accuracy. As companies aim to maintain high-quality standards and reduce operational risks, the demand for advanced CAPA capabilities within QMS platforms continues to grow rapidly.

"The Asia Pacific is expected to witness the highest growth rate during the forecast period."

The Asia Pacific is expected to experience the fastest growth in the pharmaceutical QMS market, driven by the rapid expansion of pharmaceutical manufacturing capacities, an increasing number of clinical trials outsourced to the region, and greater regulatory alignment with global standards. Additionally, the rise in digitization efforts, combined with investments in advanced IT infrastructure and automation for compliance, is fueling widespread adoption of integrated QMS platforms to improve quality assurance, simplify documentation, and maintain regulatory compliance across complex, multi-site operations.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace. The breakdown of primary participants is as mentioned below:

• By Company Type - Tier 1: 31%, Tier 2: 28%, and Tier 3: 41%
• By Designation - C-level: 31%, Director-level: 25%, and Others: 44%
• By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

Key Players in the Pharmaceutical QMS Market

The key players operating in the Pharmaceutical QMS market include Veeva Systems Inc. (US), MasterControl Solutions, Inc. (US), Honeywell International Inc. (US), IQVIA (US), Qualio, Inc. (US), Hexagon AB (Sweden), AssurX, Inc. (US), QT9 Software (US), Dassault Systemes (France), ComplianceQuest (US), Ideagen (UK), SoftExpert (Brazil), Xybion Digital Inc. (US), Intelex Technologies (Canada), Intellect, Inc. (US), AmpleLogic (India).

Research Coverage:

The report analyzes the pharmaceutical QMS market and aims to estimate its size and future growth potential across various segments based on process, application, enterprise size, end user, and region. It also provides a competitive analysis of the key players in the market, along with their company profiles, product offerings, recent developments, and key market insights strategies.

Reasons to Buy the Report

This report will help both established firms and newer or smaller companies understand the market trends, which can assist them in gaining a larger share of the market. Companies using the report can apply one or a combination of the strategies listed below to strengthen their positions in the market.

This report provides insights into:

• Analysis of key drivers (stringent regulatory compliance pressures are pushing pharma companies to adopt QMS solutions, Globalization of pharmaceutical operations is driving the need for digitalization and automation of QMS systems, cost pressures, reduce errors, and the need for operational efficiency in pharma, Increasing emphasis on risk management and adherence to regulatory standards), restraints (reluctance to adapt to new software solutions, strict data protection laws (GDPR, HIPAA) raise cybersecurity costs and slow software adoption, Concerns regarding data security & privacy), opportunities (increasing demand for specialized cloud-based software solutions in pharma manufacturing, Rising number of small & mid-sized pharma companies to propel market growth, expansion across emerging regions, fuelled by rising pharmaceutical manufacturing activities and evolving regulatory frameworks, adoption of AI and analytics to enable proactive quality management), and challenges (high initial costs of pharma QMS solutions, Variability in regulatory standards across regions, Shortages of skilled R&D and quality professionals with expertise in AI and advanced digital platforms) influencing the growth of the pharmaceutical QMS market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the pharmaceutical QMS market.
• Market Development: Comprehensive information on the lucrative emerging markets, application, process, enterprise size, end user, and region.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the pharmaceutical QMS market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the pharmaceutical QMS market, like Veeva Systems, Inc. (US), MasterControl Solutions, Inc. (US), Honeywell International Inc. (US), IQVIA (US), and Dassault Systemes (France).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMRGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET OVERVIEW
• 3.2 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE & REGION
• 3.3 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: GEOGRAPHIC SNAPSHOT
• 3.4 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Stringent regulatory compliance
    • 4.2.1.2 Globalization of pharmaceutical operations
    • 4.2.1.3 Growing demand for operational efficiency and reduce human errors
    • 4.2.1.4 Increasing emphasis on risk management and adherence to regulatory standards
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Reluctance to adopt new software solutions
    • 4.2.2.2 Strict data protection laws
    • 4.2.2.3 Data security and privacy concerns
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing demand for specialized cloud-based software solutions
    • 4.2.3.2 Rising number of small & mid-sized pharma companies
    • 4.2.3.3 Expanding pharmaceutical industry in emerging regions
    • 4.2.3.4 Adoption of AI and advanced analytics
  • 4.2.4 CHALLENGES
    • 4.2.4.1 High initial costs of implementing quality management systems
    • 4.2.4.2 Variability in regulatory standards
    • 4.2.4.3 Shortage of skilled R&D and quality professionals
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF SUBSTITUTES
  • 5.1.2 THREAT OF NEW ENTRANTS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024
  • 5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2024
• 5.6 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 CASE STUDY ANALYSIS
• 5.10 IMPACT OF 2025 US TARIFF
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRY/REGION
    • 5.10.4.1 US
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRIES
    • 5.10.5.1 Pharmaceutical companies
    • 5.10.5.2 Biotechnology companies
    • 5.10.5.3 Contract Research Organizations (CROs)

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 GENERATIVE AI & MACHINE LEARNING
  • 6.1.2 CLOUD COMPUTING & SAAS PLATFORMS
  • 6.1.3 ROBOTIC PROCESS AUTOMATION
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 MANUFACTURING EXECUTION SYSTEMS (MES)
  • 6.2.2 ENTERPRISE RESOURCE PLANNING (ERP) SYSTEMS
  • 6.2.3 ELECTRONIC DATA MANAGEMENT SYSTEMS (EDMS)
• 6.3 TECHNOLOGY/PRODUCT ROADMAP
• 6.4 PATENT ANALYSIS
  • 6.4.1 JURISDICTION ANALYSIS
  • 6.4.2 MAJOR PATENTS
  • 6.4.3 LIST OF PATENTS
• 6.5 FUTURE APPLICATIONS
  • 6.5.1 AUTOMATED AUDIT AND INSPECTION
  • 6.5.2 AI-POWERED COMPLIANCE MONITORING
  • 6.5.3 ADVANCED ANALYTICS DASHBOARDS
  • 6.5.4 MOBILE QMS APPLICATIONS
  • 6.5.5 SUPPLIER QUALITY MANAGEMENT AUTOMATION
• 6.6 IMPACT OF AI/GEN AI ON PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET
  • 6.6.1 INTRODUCTION
  • 6.6.2 MARKET POTENTIAL OF AI/GEN AI IN PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE (QMS) MARKET
  • 6.6.3 CASE STUDY RELATED TO AI/GEN AI IMPLEMENTATION
    • 6.6.3.1 Use of unified QMS platform for quality documentation
  • 6.6.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 6.6.4.1 Automated audit simulation
    • 6.6.4.2 Real-time monitoring & alerts
    • 6.6.4.3 Regulatory & compliance services
    • 6.6.4.4 Research laboratories & contract manufacturers
  • 6.6.5 USER READINESS AND IMPACT ASSESSMENT
    • 6.6.5.1 User readiness
      • 6.6.5.1.1 User A: Pharmaceutical companies
      • 6.6.5.1.2 User B: Biotechnology companies
    • 6.6.5.2 Impact assessment
      • 6.6.5.2.1 User A: Pharmaceutical companies
        • 6.6.5.2.1.1 Implementation
        • 6.6.5.2.1.2 Impact
      • 6.6.5.2.2 User B: Biotechnology companies
        • 6.6.5.2.2.1 Implementation
        • 6.6.5.2.2.2 Impact

7 REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Middle East & Africa
    • 7.1.2.5 Latin America

8 CUSTOMER LANDSCAPE & BUYING BEHAVIOUR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYERS STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA
• 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY PROCESS

• 9.1 INTRODUCTION
• 9.2 CLINICAL TRIALS
  • 9.2.1 NEED TO ENSURE CLINICAL EXCELLENCE AND REGULATORY INTEGRITY TO EXPEDITE GROWTH
• 9.3 REGULATORY COMPLIANCE
  • 9.3.1 INCREASING EMPHASIS ON COMPLYING WITH STRINGENT INTERNATIONAL STANDARDS TO AID GROWTH
• 9.4 MANUFACTURING/PRODUCTION
  • 9.4.1 GROWING FOCUS ON CONSISTENT PRODUCT QUALITY TO DRIVE MARKET
• 9.5 QUALITY ASSURANCE/QUALITY CONTROL
  • 9.5.1 INCREASING FOCUS ON CONTINUOUS MONITORING, DOCUMENTATION, AND CONTROL IN PHARMA PRODUCTION TO FAVOR GROWTH
• 9.6 DISTRIBUTION & SUPPLY CHAIN
  • 9.6.1 COMPLEX GLOBAL SUPPLY NETWORKS TO CONTRIBUTE TO GROWTH
• 9.7 COMMERCIALIZATION, MARKETING, AND SALES
  • 9.7.1 RISING INTRODUCTION OF COMPLEX THERAPIES AND EVOLVING REGULATIONS TO SUSTAIN GROWTH
• 9.8 POST-MARKET SURVEILLANCE
  • 9.8.1 GROWING FOCUS ON PRODUCT PERFORMANCE AND PATIENT SAFETY TO BOOST MARKET
• 9.9 OTHER PROCESSES

10 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 DOCUMENT CONTROL & ESOP
  • 10.2.1 NEED TO MANAGE AND CONTROL CRITICAL QUALITY DOCUMENTS TO FACILITATE GROWTH
• 10.3 CAPA (CORRECTIVE AND PREVENTIVE ACTION) MANAGEMENT
  • 10.3.1 ABILITY TO ADDRESS DETECTION, RESOLUTION, AND PREVENTION OF QUALITY AND COMPLIANCE ISSUES TO FUEL MARKET
• 10.4 AUDIT & INSPECTION MANAGEMENT
  • 10.4.1 INCREASING FOCUS ON EFFECTIVE AUDIT AND INSPECTION MANAGEMENT TO BOLSTER GROWTH
• 10.5 TRAINING MANAGEMENT
  • 10.5.1 RISING AUTOMATION AND STANDARDIZATION IN TRAINING ACTIVITIES TO ADVANCE GROWTH
• 10.6 REGULATORY & COMPLIANCE MANAGEMENT
  • 10.6.1 EVOLVING GLOBAL REGULATORY REQUIREMENTS TO ACCELERATE GROWTH
• 10.7 SUPPLIER QUALITY MANAGEMENT
  • 10.7.1 NEED TO MAINTAIN SUPPLIER RELIABILITY, MATERIAL INTEGRITY, AND REGULATORY COMPLIANCE TO SPUR GROWTH
• 10.8 RISK MANAGEMENT
  • 10.8.1 COMPLEX NATURE OF PHARMACEUTICAL OPERATIONS TO ENCOURAGE GROWTH
• 10.9 CHANGE CONTROL MANAGEMENT
  • 10.9.1 RISING TRANSITION TOWARD DIGITAL SYSTEMS TO STIMULATE GROWTH
• 10.10 OTHER APPLICATIONS

11 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY ENTERPRISE SIZE

• 11.1 INTRODUCTION
• 11.2 LARGE ENTERPRISES
  • 11.2.1 RISING DIGITAL TRANSFORMATION AND COMPLIANCE MODERNIZATION STRATEGIES TO EXPEDITE GROWTH
• 11.3 SMALL & MEDIUM ENTERPRISES
  • 11.3.1 INCREASING ADOPTION OF CLOUD-BASED, MODULAR, AND SCALABLE QMS SOLUTIONS TO AID GROWTH

12 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL COMPANIES
  • 12.2.1 INCREASING INVESTMENTS IN AI AND ANALYTICS-ENABLED QMS PLATFORMS TO PROPEL MARKET
• 12.3 BIOTECHNOLOGY COMPANIES
  • 12.3.1 STRONG FOCUS ON INNOVATION, REGULATORY COMPLIANCE, AND MANUFACTURING PRECISION TO FAVOR GROWTH
• 12.4 CONTRACT RESEARCH ORGANIZATIONS
  • 12.4.1 INCREASING CLINICAL RESEARCH, DATA MANAGEMENT, AND REGULATORY SUBMISSION ACTIVITIES TO SUSTAIN GROWTH
• 12.5 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
  • 12.5.1 CRUCIAL ROLE IN GLOBAL DRUG PRODUCTION, FORMULATION DEVELOPMENT, AND SUPPLY CHAIN MANAGEMENT TO DRIVE MARKET
• 12.6 OTHER END USERS

13 PHARMACEUTICAL QUALITY MANAGEMENT SOFTWARE MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 13.2.2 US
    • 13.2.2.1 Growing need for operational excellence in life sciences sector to boost market
  • 13.2.3 CANADA
    • 13.2.3.1 Increasing digital transformation initiatives and focus on lifecycle quality management to aid growth
• 13.3 EUROPE
  • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 13.3.2 GERMANY
    • 13.3.2.1 Robust pharma infrastructure to propel market
  • 13.3.3 UK
    • 13.3.3.1 Increasing focus on comprehensive patient safety and risk management solutions to spur growth
  • 13.3.4 FRANCE
    • 13.3.4.1 Strict regulatory environment to foster growth
  • 13.3.5 ITALY
    • 13.3.5.1 Rising compliance mandates to contribute to growth
  • 13.3.6 SPAIN
    • 13.3.6.1 Need for scalable, cost-effective, and regulatory-ready systems to augment growth
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 13.4.2 CHINA
    • 13.4.2.1 Rising clinical & manufacturing volumes and growing number of biotech companies to drive market
  • 13.4.3 JAPAN
    • 13.4.3.1 Increasing adoption of cloud systems and electronic records to aid growth
  • 13.4.4 INDIA
    • 13.4.4.1 Expanding pharmaceutical manufacturing base and increasing regulatory scrutiny from global health authorities to drive market
  • 13.4.5 AUSTRALIA
    • 13.4.5.1 Increasing shift toward electronic integrated quality ecosystems to promote growth
  • 13.4.6 SOUTH KOREA
    • 13.4.6.1 Growing focus on lifecycle quality management to propel market
  • 13.4.7 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 13.5.2 BRAZIL
    • 13.5.2.1 Growing investments in automated quality systems to drive market
  • 13.5.3 MEXICO
    • 13.5.3.1 Increasing emphasis on data integrity and electronic documentation to boost market
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 13.6.2 GCC COUNTRIES
    • 13.6.2.1 Saudi Arabia
      • 13.6.2.1.1 Increasing local manufacturing and enhanced regulatory compliance to promote growth
    • 13.6.2.2 UAE
      • 13.6.2.2.1 Rising regulatory modernization and national manufacturing initiatives to sustain growth
    • 13.6.2.3 Rest of GCC countries
  • 13.6.3 SOUTH AFRICA
    • 13.6.3.1 Evolving regulatory expectations and digitalization trends to fuel market
  • 13.6.4 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 14.3 REVENUE SHARE ANALYSIS
• 14.4 MARKET SHARE ANALYSIS
• 14.5 SOFTWARE COMPARISON
• 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.6.1 STARS
  • 14.6.2 EMERGING LEADERS
  • 14.6.3 PERVASIVE PLAYERS
  • 14.6.4 PARTICIPANTS
  • 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.6.5.1 Company footprint
    • 14.6.5.2 Region footprint
    • 14.6.5.3 Process footprint
    • 14.6.5.4 Application footprint
    • 14.6.5.5 Enterprise size footprint
    • 14.6.5.6 End-user footprint
• 14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.7.1 PROGRESSIVE COMPANIES
  • 14.7.2 RESPONSIVE COMPANIES
  • 14.7.3 DYNAMIC COMPANIES
  • 14.7.4 STARTING BLOCKS
  • 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 14.7.5.1 Detailed list of key startups/SMEs
    • 14.7.5.2 Competitive benchmarking of key startups/SMEs
• 14.8 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.8.1 COMPANY VALUATION
  • 14.8.2 FINANCIAL METRICS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS
  • 14.9.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 HONEYWELL INTERNATIONAL INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches and approvals
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths/Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses/Competitive threats
  • 15.1.2 IQVIA
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
      • 15.1.2.3.2 Other developments
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths/Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses/Competitive threats
  • 15.1.3 VEEVA SYSTEMS INC.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches and approvals
      • 15.1.3.3.2 Deals
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths/Right to win
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses/Competitive threats
  • 15.1.4 MASTERCONTROL SOLUTIONS, INC.
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths/Right to win
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses/Competitive threats
  • 15.1.5 DASSAULT SYSTEMES
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 MnM view
      • 15.1.5.3.1 Key strengths/Right to win
      • 15.1.5.3.2 Strategic choices
      • 15.1.5.3.3 Weaknesses/Competitive threats
  • 15.1.6 QUALIO
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
  • 15.1.7 HEXAGON AB
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product launches and approvals
      • 15.1.7.3.2 Deals
  • 15.1.8 ASSURX, INC.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 QT9 SOFTWARE
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product launches and approvals
      • 15.1.9.3.2 Deals
  • 15.1.10 COMPLIANCEQUEST
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Deals
  • 15.1.11 IDEAGEN
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product launches and approvals
      • 15.1.11.3.2 Deals
  • 15.1.12 SOFTEXPERT
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Deals
  • 15.1.13 INSTEM
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Deals
  • 15.1.14 INTELEX TECHNOLOGIES
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product launches and approvals
      • 15.1.14.3.2 Expansions
  • 15.1.15 INTELLECT, INC
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Product launches and approvals
  • 15.1.16 AMPLELOGIC
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Deals
• 15.2 OTHER PLAYERS
  • 15.2.1 INSTANTGMP
  • 15.2.2 SIMPLERQMS
  • 15.2.3 DOT COMPLIANCE LTD.
  • 15.2.4 SNIC SOLUTIONS
  • 15.2.5 QUALITYZE
  • 15.2.6 SCIGENIQ
  • 15.2.7 KIVO, INC.
  • 15.2.8 GMP SOFTWARE INDIA PVT. LTD.
  • 15.2.9 VMT SOFT SOL PVT. LTD.

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Key data from primary sources
    • 16.1.2.2 Key primary participants
    • 16.1.2.3 Breakdown of primary interviews
    • 16.1.2.4 Key industry insights
• 16.2 MARKET SIZE ESTIMATION
• 16.3 DATA TRIANGULATION
• 16.4 FACTOR ANALYSIS
• 16.5 RESEARCH ASSUMPTIONS
  • 16.5.1 MARKET SIZING ASSUMPTIONS
  • 16.5.2 STUDY ASSUMPTIONS
• 16.6 RESEARCH LIMITATIONS AND RISK ASSESSMENT
  • 16.6.1 RESEARCH LIMITATIONS
    • 16.6.1.1 Methodology-related limitations
    • 16.6.1.2 Scope-related limitations
  • 16.6.2 RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS